Literature DB >> 8109552

Usefulness of L-thyroxine to improve cardiac and exercise performance in idiopathic dilated cardiomyopathy.

P Moruzzi1, E Doria, P G Agostoni, V Capacchione, P Sganzerla.   

Abstract

The short-term effects of L-thyroxine (100 micrograms/day, 10 patients) and placebo (10 patients) on idiopathic dilated cardiomyopathy were compared. Before and at the end of the treatment, a hemodynamic study was performed in the control state and during dobutamine infusion. A cardiopulmonary exercise test was also performed with hemodynamic monitoring. An echocardiogram was recorded in the control state and during acute changes of left ventricular afterload. Plasma levels of triiodothyronine, thyroxine, thyroid-stimulating hormone and norepinephrine were measured. Placebo was ineffective. After administration of L-thyroxine all patients had normal thyroid function. The increase in left ventricular ejection fraction and the rightward shift of the slope of left ventricular ejection fraction/end-systolic stress relation (p < 0.05) indicated an improvement in the cardiac inotropic state. This proved to be independent of adrenergic influences by the unchanged beta 1 response to dobutamine. A decrease in resting systemic vascular resistances and an increase in cardiac output (p < 0.05) were also observed. Cardiopulmonary effort parameters improved (p < 0.05) without hemodynamic changes at peak exercise. It is concluded that L-thyroxine short-term administration improves cardiac and exercise performance in patients with chronic heart failure, without modifying the adrenergic support to the heart and the circulatory parameters at peak exercise.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8109552     DOI: 10.1016/0002-9149(94)90011-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  20 in total

Review 1.  Nonthyroidal illness and the cardiorenal syndrome.

Authors:  Christiaan L Meuwese; Olaf M Dekkers; Peter Stenvinkel; Friedo W Dekker; Juan J Carrero
Journal:  Nat Rev Nephrol       Date:  2013-09-03       Impact factor: 28.314

Review 2.  The role of thyroid hormone in the pathophysiology of heart failure: clinical evidence.

Authors:  E Galli; A Pingitore; G Iervasi
Journal:  Heart Fail Rev       Date:  2008-12-27       Impact factor: 4.214

3.  Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka
Journal:  Thyroid       Date:  2014-12       Impact factor: 6.568

Review 4.  Translating thyroid hormone effects into clinical practice: the relevance of thyroid hormone receptor α1 in cardiac repair.

Authors:  Constantinos Pantos; Iordanis Mourouzis
Journal:  Heart Fail Rev       Date:  2015-05       Impact factor: 4.214

5.  Myocardial Induction of Type 3 Deiodinase in Dilated Cardiomyopathy.

Authors:  Ari J Wassner; Rebecca H Jugo; David M Dorfman; Robert F Padera; Michelle A Maynard; Ann M Zavacki; Patrick Y Jay; Stephen A Huang
Journal:  Thyroid       Date:  2017-04-05       Impact factor: 6.568

6.  In vivo selective expression of thyroid hormone receptor α1 in endothelial cells attenuates myocardial injury in experimental myocardial infarction in mice.

Authors:  Jorge Suarez; Hong Wang; Brian T Scott; Haiyun Ling; Ayako Makino; Eric Swanson; Joan Heller Brown; Jorge A Suarez; Shera Feinstein; Julieta Diaz-Juarez; Wolfgang H Dillmann
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-05-21       Impact factor: 3.619

Review 7.  Thyroid hormone and heart failure.

Authors:  Ursula Maria Schmidt-Ott; Deborah Davis Ascheim
Journal:  Curr Heart Fail Rep       Date:  2006-09

8.  High prevalence of non-thyroidal illness syndrome in patients at long-term care facilities.

Authors:  Joaquin Lado-Abeal; Carmen Diaz; Gilbert Berdine; Kenneth Iwuji; David Araujo-Vilar; Natalia Lampon-Fernandez; Min Wang; Santiago Lojo; Alfonso Rodriguez-Perez; Ana Marcella Rivas
Journal:  Endocrine       Date:  2020-04-28       Impact factor: 3.633

9.  Thyroid hormone induces cardiac myocyte hypertrophy in a thyroid hormone receptor alpha1-specific manner that requires TAK1 and p38 mitogen-activated protein kinase.

Authors:  Koichiro Kinugawa; Mark Y Jeong; Michael R Bristow; Carlin S Long
Journal:  Mol Endocrinol       Date:  2005-04-14

10.  Gene polymorphisms and thyroid function in patients with heart failure.

Authors:  Ioannis Vasiliadis; Genovefa Kolovou; Vana Kolovou; Vasiliki Giannakopoulou; Maria Boutsikou; Niki Katsiki; Evaggelia Papadopoulou; Sophie Mavrogeni; Konstantina Sorontila; Costas Pantos; Dennis V Cokkinos
Journal:  Endocrine       Date:  2013-03-30       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.